Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Apple Turns 50: From Garage Startup to AI Crossroads 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
GAITHERSBURG, Md., Sept. 06, 2017 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, taking place September 11-12 at the Lotte New York Palace Hotel in New York City.
Presentation Details
| Date: | Tuesday, September 12 |
| Time: | 10:25am Eastern Time |
| Location: | Lotte New York Palace Hotel, Kennedy I Ballroom |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.
Altimmune Contacts Bill Enright President and CEO Phone: 240-654-1450 Email: [email protected] Michael Rice Investor Relations Phone: 646-597-6979 Email: [email protected]
